HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on LAVA Therapeutics (NASDAQ:LVTX) and maintains a $6 price target.
March 21, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on LAVA Therapeutics with a $6 price target.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst like Arthur He from HC Wainwright & Co. is likely to instill confidence among investors and could positively influence LAVA Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded firms, often impact investor sentiment and can lead to price movements.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100